1	Assessing Population-level Target Product Profiles of
2	Broadly-protective Human Influenza A Vaccines
3	Qiqi Yang ¹ , Sang Woo Park ¹ , Chadi Saad-Roy ^{2,3} , Isa Ahmad ⁴ , Cécile Viboud ⁵ , Nimalan Arinaminpathy ^{4,*} , and Bryan T. Grenfell ^{1,6,*}
5	¹ Department of Ecology and Evolutionary Biology, Princeton University, NJ, USA
6	² Miller Institute for Basic Research in Science, University of California, Berkeley,
7	California, USA
8	³ Department of Integrative Biology, University of California, Berkeley, California,
9	USA
10	⁴ MRC Centre for Global Infectious Disease Analysis, Department of Infectious
11	Disease Epidemiology, School of Public Health, Imperial College London, UK
12	⁵ Division of International Epidemiology and Population Studies, Fogarty
13	International Center, National Institutes of Health, Bethesda, Maryland, USA
14	⁶ Princeton School of Public and International Affairs, Princeton, NJ, USA
15	February 2, 2024

 $^{16} \qquad ^{*} Correspondence: \ nim.pathy@imperial.ac.uk, \ grenfell@princeton.edu$

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract 17 Influenza A has two main clades, with stronger cross-immunity to reinfection within than be-18 tween clades. Here, we explore the implications of this heterogeneity for proposed cross-protective 19 influenza vaccines that may offer broad, but not universal, protection. While the development 20 goal for the breadth of human influenza A vaccine is to provide cross-clade protection, vaccines in 21 current development stages may provide better protection against target clades than non-target 22 clades. To evaluate vaccine formulation and strategies, we propose a novel perspective: a vaccine 23 population-level target product profile (PTPP). Under this perspective, we use dynamical mod-24 els to quantify the epidemiological impacts of future influenza A vaccines as a function of their 25 properties. Our results show that the interplay of natural and vaccine-induced immunity could 26 strongly affect seasonal clade dynamics. A broadly protective bivalent vaccine could lower the 27 incidence of both clades and achieve elimination with sufficient vaccination coverage. However, 28 29 a univalent vaccine at low vaccination rates could permit a resurgence of the non-target clade when the vaccine provides weaker immunity than natural infection. Moreover, as a proxy for 30 pandemic simulation, we analyze the invasion of a variant that evades natural immunity. We find 31 that a future vaccine providing sufficiently broad and long-lived cross-clade protection at a suffi-32 ciently high vaccination rate, could prevent pandemic emergence and lower the pandemic burden. 33 This study highlights that as well as effectiveness, breadth and duration should be considered in 34 epidemiologically informed TPPs for future human influenza A vaccines. 35

³⁶ Keywords: Human influenza A; Vaccine; Dynamic model; Cross immunity; Immuno-epidemiology

37 1 Introduction

Seasonal epidemics and occasional pandemics of human influenza A viruses cause substantial public 38 health burden. Although vaccination is an important approach to mitigate this burden [3], current 39 influenza A vaccines have significant limitations. First, they need to be evaluated annually for updates, 40 due to the rapid turnover of antigenic variants. Second, existing vaccines can have low efficacy and 41 narrow specificity (therefore cannot pre-emptively target potential pandemic influenza variants [14, 42 24, 15). In addition, the frequent update of current vaccines may worsen vaccine hesitancy of 43 individuals and increase the economic burden of vaccine purchases [2]. To tackle this challenge, there 44 have been great efforts to develop a new generation of broadly-protective influenza vaccines [16, 22, 45 17, 1, 15]. However, there remain challenges in establishing broad protection. For example, a vaccine 46 that targets one clade (e.g., clade 1) of human influenza A by raising stem-targeted antibodies might 47 provide limited cross-protection to the other clade (e.g., clade 2) [17]. Widespread use of such a 48 vaccine could have complex effects on influenza epidemiology where both clade 1 and 2 are already 10 endemic, in ways that are not yet fully understood. 50 Here we construct a compartmental model to quantify vaccine impacts on seasonal influenza dy-51 namics and potential pandemic invasions. The model incorporates host immunological history and 52

clade co-existence. We model cross-clade interactions using H1N1 and H3N2 as respective represen-53 tatives of H1 and H3 clades, choosing model parameters to match the broad behaviour of human 54 influenza A in the USA in recent seasons. We assume the vaccine provides clade-level protection, i.e., 55 strong cross-protection within one clade of influenza A but weaker cross-protection between clades. 56 We focus on the impact of vaccinal immunity strength and duration on 1) seasonal strain dynamics 57 of endemic infections and 2) immune escape at inter- and intra-clade levels, mimicking pandemic 58 emergence. We can frame these variables by extending the standard notion of the Target Product 59 Profile (TPP), which typically focuses on vaccine benefits to the individual, such as effectiveness. 60 Although the TPP is an essential tool, we argue that its value for future influenza vaccines could 61 be strengthened by considering the population-level processes (beyond vaccine effectiveness) more 62 explicitly. 63

$_{\rm 64}$ 2 Methods

65 2.1 Mathematical model

⁶⁶ When modelling human influenza strain dynamics, incorporating sufficient antigenic variation comes ⁶⁷ at the cost of complex host immune history. History-based models [27] take the host view, to track host ⁶⁸ infection history by different strains without including large variations in antigenicity. In contrast, ⁶⁹ while not including host immune history, status-based models [12] take the pathogen view, to track ⁷⁰ their impacts on hosts' future infections by all other strains. To balance the complexity of antigenic ⁷¹ variation and host immune history, we focus on the clade level of the influenza A virus phenotype ⁷² and include relevant host immune history. We use i = 1 and i = 2 to represent the 'H1' and ⁷³ 'H3' clades, respectively. We construct our model (Figure 1), based on a previous 2-strain SIRS ⁷⁴ model on pertussis [19, 20] that incorporates host immune history. Our model allows immunity to ⁷⁵ reduce susceptibility against subsequent infections, and we refer to the proportional reduction in ⁷⁶ susceptibility as the *strength of cross-immunity* (using θ for infection-induced immunity, and τ for ⁷⁷ vaccine-induced immunity).

Hosts acquire immunity either via natural infection or vaccination. In the example of H1, we 78 define transmission rate as β_1 . Following natural infection, strain-transcending immunity is induced 79 first, i.e., short-term immunity against all clades, which can potentially shape the genetic diversity 80 of seasonal human influenza [10]. This immunity wanes at rate σ_T . After it wanes, the host can get 81 infected by another clade with reduced susceptibility $(\beta_2(1-\theta_1))$; or immunity can further wane (at 82 rate σ_1), making the host fully susceptible to infections from both clades. After the host is infected 83 with both clades, they are fully protected against all infections until immunity wanes. This immunity 84 can wane (at rate σ_2), making the host susceptible to the second clade again. 85

⁸⁶ Hosts acquire vaccinal immunity via vaccination at rate ρ . This immunity wanes at rate σ_V . We ⁸⁷ assume that vaccinal immunity can further enhance infection-induced immunity, and the resulting ⁸⁸ cross-immunity is modelled as a product of infection and vaccinal immunity. For example, a host ⁸⁹ recovered from H1 primary infection who is vaccinated has reduced susceptibility against H3 of ⁹⁰ $\beta_2(1-\theta_1)(1-\tau_1)$. We ignore the vaccine's boosting effect on homotypic immunity when the host has ⁹¹ already acquired 'perfect' immunity (100% susceptibility reduction) against the clade via infection.

Regarding vaccine breadth, we model the following three vaccine scenarios:

• Bivalent vaccine. The vaccine reduces susceptibility against both clades proportionally by τ_1 and τ_2 , respectively. The duration of vaccinal immunity is $\frac{1}{\sigma_V}$. The vaccination rate is $\rho_1 = \rho_2 = \rho$. A bivalent vaccine is the ultimate goal of broadly-protective vaccine development; however, during initial development stages, it is likely that the vaccines would be univalent [17]:

• Univalent H1 vaccine. The vaccine fully reduces susceptibility against H1 clade ($\tau_2 = 1$) and partially against H3 clade ($\tau_1 < 1$). The duration of the immunity is $\frac{1}{\sigma_V} = \frac{1}{\sigma_{V_1}}$; the vaccination rate is $\rho = \rho_1$.

• Univalent H3 vaccine. The vaccine fully reduces susceptibility against H3 clade ($\tau_1 = 1$) and partially against H1 clade ($\tau_2 < 1$). The duration of the immunity is $\frac{1}{\sigma_V} = \frac{1}{\sigma_{V_2}}$. The vaccination rate is $\rho = \rho_2$.

In each scenario, the strength and duration of the vaccinal immunity is same as that of infectioninduced immunity $(k_1 = \frac{\tau_{1,2}}{\theta_{1,2}} = 1, k_2 = \frac{\sigma_{1,2}}{\sigma_{V_{1,2}}} = 1)$. In further analysis, we vary k_1 or k_2 to be 0.5 or 2 to explore the vaccine's impacts on seasonal epidemics (Figure 2 and 3).

In addition, our model is *seasonally forced* because seasonality is a frequent characteristic of nonpandemic human influenza incidence [6]. The transmission rate $\beta_1(t)$ and $\beta_2(t)$ is determined by a standard sinusoidal function [9, 7]:

$$\beta_i(t) = R_0^{(i)}(\gamma_i + \mu)(1 + a\cos(2\pi t)) \tag{1}$$

where i = 1, 2 represents H1 or H3 clade, $R_0^{(i)}$ is the basic reproductive number of the clade i, γ is the recovery rate, μ is the birth rate and a is amplitude of the sinusoidal forcing. All parameters in the model and the sources of their values are listed in Table S2.

The model (Figure 1) is described by the ordinary differential equations in Supplementary materials S1.2. We set the initial conditions by assuming a 0.1% prevalence for H1 and H3 infections separately (therefore 0.2% in total). We assume that the remaining 99.8% of the population is fully susceptible. We then run deterministic simulations by numerically integrating the model for 100 years at semiweekly time steps to allow the system to reach its endemic phase. Subsequent analyses are based on this endemic phase reached from the initial condition. Sensitivity tests show that different initial conditions would have negligible effect on our results (Figure S1 and S2).



Figure 1: Model diagram. Births and deaths at rate μ per capita are not shown. The dashed lines show waning of immunity. The solid lines show infection, vaccination, or recovery. Each squared compartment can have up to four equal-sized 'sub-squares' representing infection or immunity status. The left top sub-square represents primary infection; the right top is secondary infection. The infection is either of H1 clade (pink) or H3 clade (blue). The bottom two sub-squares denote strain-transcending immunity (yellow) and vaccinal immunity (green). Definitions of all compartments are in Table S1 and all parameters in Table S2. The ordinary differential equations of the model are in Supplementary S1.2

119 2.2 Model calibration

¹²⁰ To ensure that the model captures subtype dynamics broadly consistent with that observed in temper-¹²¹ ate regions, we use influenza surveillance data during the 2004/2005-2018/2019 seasons in the USA. We use data on subtypes H1N1 and H3N2 to represent H1 and H3 clades. We omit the pandemic period (2008-2009, 2009-2010 and 2010-2011 seasons), shown as grey area in Figure S3. In order to capture broad features of influenza A epidemiology in the USA, we match model simulations to summary statistics of human influenza A incidence rates in the USA (Figure S3) as listed below: the auto-correlation and coefficient of variation of subtype incidence and cross-correlation between subtype incidence. Key transmission parameters (Table S2) are drawn from a previous human influenza disease-dynamic modeling study focusing on Hong Kong [26].

The incidence rate (Figure S3) is estimated by combining influenza-like illness (ILI) surveillance data and laboratory-confirmed subtyping data as in the equation below, which is adapted from a previous study [8].

Weekly incidence rate of subtype x = Outpatient ratio (Ratio of ILI patients among all hospital visits) * Ratio of influenza positive sample among all testings * Ratio of subtype x among all positive samples

where x =H1N1 or H3N2, and we used the ILI surveillance data weighted by the state population. Outpatient illness surveillance data and viral surveillance data were downloaded from FluView (US Centers for Disease Control and Prevention, CDC [11]). Viral surveillance data were collected from the US World Health Organization (WHO) Collaborating Laboratories and National Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories [23].

Given the crudeness of the available data, we do not aim to capture detailed incidence in each 140 season. Instead, we aim to match high-level patterns in the data, particularly in relation to the 141 dominance patterns of the subtypes through time. We adjust values of three parameters: infection-142 induced cross-immunity strength (θ_1 and θ_2) and amplitude of sinusoidal seasonal forcing function 143 (a) (to adjust the incidence). The incidence at each time step is calculated as the new infections 144 with the focal clade regardless of the hosts' immune statuses. The optimization metric is the sum 145 of the absolute distance between simulation and data [11] of three summary statistics, including I) 146 correlation between H1 and H3 seasonal incidence, II) coefficient of variation of H1 (and H3) seasonal 147 incidence, III) auto-correlation of H1 (and H3) seasonal incidence. We run deterministic simulations 148 by numerically integrating the model for 2000 years at semi-weekly time steps. We then calculated 149 the statistics for every 12-year period (the first 800 years were removed as burn-in) and obtained a 150 distribution of summary statistics. The optimization metric distribution across the parameter space 151 (Figure S4) shows that when the seasonal forcing is weak, i.e., a = 0.04, the distances between 152 simulation and data are the smallest, which is consistent with previous studies [9, 7]. For further 153 analysis, we use the best parameter set $\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$ that gives the minimal distance 154 across the parameter space (Figure S5). For sensitivity test, we choose a moderately-fit parameter set 155 $\theta_1 = 0.55, \theta_2 = 0.35, a = 0.04$ that is more common across different a than other parameters (Figure 156 S6). The results show that both parameter sets well match the dominance patterns of the subtypes 157 in the data (Figure S7 and S8). 158

¹⁵⁹ 2.3 Invasion analysis of antigenic variants

To test the impact of the strength and duration of vaccinal immunity on pandemic emergence, we 160 model a scenario where the population is exposed to (for simplicity) only one clade and is vaccinated 161 against this clade. We simulate the model for 600 years at semi-weekly time steps to reach the 162 endemicity of this clade. Then, a pandemic variant that fully escapes natural immunity is introduced 163 to the population. We explore a range of basic reproduction numbers of the pandemic variant $(R_0^{(1)})$ 164 holding the endemic strain's $R_0^{(2)}$ at 1.6, where i) $R_0^{(1)} = 1$, ii) $1 < R_0^{(1)} < R_0^{(2)}$, iii) $R_0^{(1)} = R_0^{(2)}$, and 165 iv) $R_0^{(1)} = 2R_0^{(2)}$. To test the vaccine impact, we vary the vaccination rate from 0 to 2% per week, 166 the susceptibility reduction of the vaccine against the pandemic variant from 0 to 100% and vaccine 167 immunity duration from 0.5, 1, 2, 4, 8 to 16 years. Using species invasion analysis similar to a previous 168 study [20], we analyze the growth rate of the pandemic variant in the population as shown in the 169 equation S7 (See Supplementary materials S1.3). We then numerically integrate the equations S1 to 170 obtain deterministic dynamics of the system following the introduction of the pandemic variant with 171 an incidence of one-millionth of the population size. The pandemic variant approximately follows 172 exponential growth at the initial stage of invasion; therefore, we quantify the initial growth rate as 173 the difference between the logarithm of the pandemic variant's incidence on the third day and that on 174 the second day, divided by the time difference (1 day). To quantify the persistence of the pandemic 175 variant, we use trough depth, i.e., the minimal incidence of the pandemic variant after its initial peak. 176

177 3 Results

Impacts on seasonal epidemics of vaccinal immunity breadth, strength and duration

For each vaccinal immunity breadth scenario (see Methods), we explore a range of different strengths (Figure 2) and durations of vaccine-induced cross-protection (Figure 3) relative to infection-induced immunity. The robustness of the results is confirmed using not only the best-fitting parameters set, but also alternative, moderately-fitting parameter sets (Figure S9 and S10).

A bivalent vaccine (top row in Figure 2 and 3) would eliminate both clades without the potential 184 of an incidence increase. The vaccination rates required to eliminate H1 and H3 are lower when the 185 vaccinal immunity is stronger or longer. Due to higher R_0 , the H3 clade requires a higher vaccination 186 rate to eliminate. When the vaccine targets one clade (either H1 or H3 clade, bottom two rows in 187 Figure 2), providing the same or weaker immunity than natural infection (the left and middle columns 188 189 in Figure 2), low vaccination rates could lead to an increase in the incidence of the non-target clade. The peak of the incidence occurs at the vaccination rate that eliminates the target clade. In contrast, 190 when the vaccine-induced cross-immunity is stronger than natural immunity, the incidence of the 191 off-target clade always decreases with the vaccination rate (the right column in Figure 2). The reason 192 for this contrast lies in the interplay of natural and vaccinal cross-immunity: 193

• When the vaccination rate is 0, the cross-immunity is completely infection-induced.

¹⁹⁴

- Before the target clade is eliminated, the cross-immunity comprises vaccinal and natural immunity that is stronger than vaccinal immunity alone.
- 197

198

• When the target clade is eliminated, the cross-immunity against the non-target clade is completely vaccine-induced.

Therefore, depending on the relative strength of vaccinal and natural immunity, the combined strength
 of vaccinal and natural cross-immunity becomes either stronger or weaker with the increase in vaccination rate.

Similarly, when the strength of vaccinal immunity is the same as infection-induced immunity, the 202 H1 or H3 vaccine could eliminate the target clade at a low vaccination rate (bottom two rows in Figure 203 3). However, the incidence of the non-target clade could increase slightly at low vaccination rates. The 204 shorter the duration of vaccine immunity compared to the infection immunity, the higher the minimum 205 vaccination rate required to prevent any incidence increase of non-target clade. Additionally, when 206 vaccine-induced immunity duration is twice as long as infection-induced immunity, the vaccination 207 rate required for eliminating one clade and reaching the incidence plateau of the other clade is 208 correspondingly reduced to 50% (Figure 3). 209

3.2 Impacts on pandemic emergence and persistence of vaccinal immunity breadth, strength and duration

How might vaccinal cross-immunity strength and duration collectively impact the emergence of a 212 pandemic variant in a vaccinated population? As a simple representation of pandemic emergence, 213 we assume the population is exposed to only one endemic clade, e.g., H3 clade (i.e., i = 2), and is 214 vaccinated by the vaccine targeting H3 clade. Then it is exposed to a pandemic variant. We made 215 a pessimistic assumption that H3 infection does not induce cross-immunity against the pandemic 216 variant. The analytical result (Supplementary materials S1.3) shows that even when the pandemic 217 variant has a lower basic reproductive number than the endemic strain, i.e., $R_0^1 < R_0^2$, the pandemic 218 can still emerge in the population, depending on the vaccine characteristics. Results in Figure 4 show 219 how the initial growth rate of the pandemic variant depends on vaccine characteristics, including 220 vaccination rate and immunity strength and duration. First, the boundary of pandemic emergence 221 (shown with the red curve) moves towards less susceptibility reduction by the vaccine, for lower 222 values of R_0^1 (Figure 4). In line with intuition, this indicates that the threshold of vaccine cross-223 immunity strength to prevent the pandemic is strongly dependent on the basic reproductive number 224 of the pandemic variant. In addition, longer vaccine-induced cross-immunity duration lowers the 225 vaccination rate threshold and vaccinal immunity strength level for preventing pandemic emergence. 226 Following introduction, the pandemic variant can either 1) fail to emerge, 2) emerge and co-exist 227 with the endemic strain, or 3) emerge and eliminate the endemic strain. Under limited vaccinal 228 protection, the endemic and pandemic strains co-exist (corresponding colored areas in Figure 5 and 229 S11 under the same vaccine characteristics). Vaccination characteristics and fitness of the pandemic 230 strain decide the emergence of the pandemic strain (Figure 5 and S12). Any of the following vaccine 231



Figure 2: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *strengths* (columns, defined as $k_1 = \frac{\tau_i}{\theta_i}$), with changes of vaccination rate (%) per week (x axis). The results are calibrated with the best-fitting parameters ($\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$). Other parameter values are in Table S2



Figure 3: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *durations* (columns, defined as $k_2 = \frac{\sigma_i}{\sigma_V}$), with changes of vaccination rate (%) per week (x axis). The parameters are same as in 2.



Figure 4: Emergence of a pandemic variant with the basic reproduction number R_0^1 (column), which is measured by initial growth rate coloured by greens (failure of emergence) and yellow-to-reds (emergence), under vaccination of different immunity strength (y axis), duration (row) and vaccination rate ρ (%) per week (x axis). In these simulations, the pandemic variant completely escapes natural cross-immunity ($\theta_2 = 0$), the average infection-acquired immunity period is 2.7 years, the average infectious period is 3.03 days, and the average life span is 75 years. The initial growth rate is defined as the incidence growth of the pandemic variant between the second and third day of the invasion.

characteristics could more easily prevent the emergence of the pandemic variant: higher vaccination 232 rate, longer immunity duration and more susceptibility reduction against the pandemic variant (Figure 233 5). Interestingly, at the same vaccination rate, more susceptibility reduction could increase the 234 incidence during the trough following invasion (Figure S12). This could be because stronger cross-235 immunity against the pandemic variant allows slower spread of the variant at the beginning. Due 236 to the demographic stochasticity, when the trough depth is lower than 10^{-6} , the pandemic variant 237 could still become extinct (e.g., Figure S12) in a very large city. Therefore, we define the pandemic 238 persistence threshold (orange curve in Figure 5) as 10^{-6} . Additionally, the result suggests that the 239 pandemic invasion trough depth might have a non-monotonic relationship with vaccine strength and 240 vaccination rate. This non-monotonic relationship on persistence has been shown in other studies 241 [18].242

243 4 Discussion

While TPPs of a vaccine are rightly informed by individual-level factors such as safety and efficacy against a symptomatic endpoint, the population-level epidemiological impacts of vaccines are less considered. By quantifying the potential epidemiological impacts, our work illustrates how TPPs



Figure 5: Persistence of the pandemic variant 5 years after its emergence, measured by trough depth of its incidence ((the minimal incidence), under vaccination of different immunity strength (y axis), duration (row) and vaccination rate ρ (%) per week (x axis), with different basic reproduction number R_0^1 (column). The grey area is when the pandemic variant fails to emerge. The black curves indicate the transition between persistence and failure in the emergence of the pandemic variant. Other parameters are same as those in Figure 4.

247 could be complemented with population-level effectiveness, breadth, and immunity duration. What

 $_{\it 248}$ $\,$ indicators would be important in such population-level TPPs? Based on our analysis, Table 1 lists

²⁴⁹ some important characteristics, as well as some that should be addressed in future studies.

250

Vaccine characteristic Preferred Study sources Complementary vaccines for all clades (in Breadth This study the absence of universal protection) No weaker than infection-induced immu-Strength* This study nity No shorter than infection-induced immu-Duration* This study nity Susceptibility-reduction (preferred to in-Immunity type This study and [5] fectiousness reduction) Dose regimen Annual vaccination [21]High rate (the sufficient rate depends on Vaccination rate This study the vaccination strategy) Vaccination acceptability and achievable Future studies coverage Interaction of vaccine Future studies immunity with prior immunity Future Evolutionary impacts studies on seasonal influenza building on existviruses ing literature ([4])

Table 1: Population-level Target Product Profiles (PTPPs) for broadly-protective human influenza A vaccines

* In practice, the strength and duration of the vaccine are usually correlated [14].

Specifically, our results show how the interplay between natural and vaccine-induced cross-immunity 251 affects both clade dynamics and pandemic emergence. In this process, both vaccine immunity strength 252 and cross-immunity strength are important. Notably, when a broadly protective vaccine provides lim-253 ited protection against a non-target clade, this clade might cause a larger epidemic at low vaccination 254 rates, than in the absence of vaccination. In contrast, the bivalent vaccine scenario never permits a 255 larger epidemic and could eliminate both clades at similar vaccination rates. Therefore, our results 256 highlight that adopting vaccines for against both clades would be essential for the broadly-protective 257 vaccine deployments. 258

Additionally, when a vaccine-escape variant emerges, the population might be more vulnerable to the variant [5] than in the absence of the vaccine. For example, in theory, a vaccine providing cross-immunity by reducing infectiousness would reduce transmission at the population level and improve herd immunity in the long term [4]; however, such a vaccine might permit larger pandemics when the coverage is low [5], by increasing the population's vulnerability to a pandemic invasion by a non-target variant. These existing studies focused on hypothesized vaccines that only reduce the infectiousness without reducing the susceptibility to infection, consistent with the effect of nonsterilizing T-cell immunity. Currently, promising vaccine candidates are being developed to reduce susceptibility to infection, e.g., one targeting the HA-stalk region [17]. Our results illustrate the potential of the epidemiological impacts of such vaccines: they might have a lower risk of permitting a larger pandemic than those that reduce infectiousness.

However, due to the lack of relevant experimental data on the mechanisms of vaccinal immunity, 270 our results remain theoretical. Other caveats of this work include that the model assumes a homoge-271 neous infection in a well-mixed population; for example, age or spatial structure of hosts or antigenic 272 imprinting [13] could favor the invasion of the pandemic variant. The model also does not incorpo-273 rate subtype diversity within clades of influenza viruses, nor does it address the effect of immunity 274 on severity. In addition, we did not assess potential evolutionary impacts of the broadly-protective 275 vaccines [4]. Furthermore, our model calibration only matches the subtype dominance pattern. The 276 model could be refined by fitting time series of influenza incidence in the future, if more refined 277 data become available. Finally, we assume that vaccine-induced and infection-induced immunity are 278 independent, but in practice, they might oppose each other due to a possible ceiling effect, i.e., the 279 level of protection cannot exceed a threshold. Nonetheless, even our simple epidemiological model 280 provides insights into the potential value of population-level TPPs: the importance of considering 281 immunity breadth, strength and duration in broadly-protective vaccine design and deployments. To 282 advance understanding of population-level TPPs, future studies could incorporate virus genomic data 283 and human immune data by applying immuno-epidemiological phylodynamic modelling approaches. 284 These advances depend crucially on maintaining and enhancing epidemiological, genomic, and im-285 mune surveillance against influenza and other imperfectly-immunizing pathogens. 286

287 5 Acknowledgements

This work was funded by FluLab. Q.Y. acknowledges funding from the Center for Health and Wellbe-288 ing, Princeton University, via Graduate Funding for Health-Focused Research. S.W.P. acknowledges 289 funding from Princeton University via a Charlotte Elizabeth Procter Fellowship. C.M.S.-R. acknowl-290 edges funding from the Miller Institute for Basic Research in Science of UC Berkeley via a Miller 291 Research Fellowship. B.T.G acknowledges support from Princeton Catalysis Initiative. The authors 292 thank Bin Zhang for suggesting potential datasets. Disclaimer: The findings and conclusions in this 293 report are those of the authors and do not necessarily represent the official position of the US National 294 Institutes of Health or Department of Health and Human Services. 295

6 Author contributions

N.A. and B.T.G. contributed to funding acquisition and supervision. Q.Y., S.W.P., C.M.S.-R., N.A.,
and B.T.G. contributed to model conceptualization. Q.Y. and S.W.P. contributed to formal analysis
and visualization. Q.Y., C.V., C.M.S.-R. and I.A. contributed to data curation. Q.Y., N.A. and

³⁰⁰ B.T.G. wrote the original draft. All authors contributed to reviewing and editing the draft.

301 References

- [1] Claudia P. Arevalo et al. "A Multivalent Nucleoside-Modified mRNA Vaccine against All Known
 Influenza Virus Subtypes". In: Science 378.6622 (Nov. 2022), pp. 899–904. DOI: 10.1126/
 science.abm0271.
- [2] Nimalan Arinaminpathy et al. "A Global System for the next Generation of Vaccines". In:
 Science 376.6592 (Apr. 2022), pp. 462-464. DOI: 10.1126/science.abm8894.
- [3] Nimalan Arinaminpathy et al. "Estimating Direct and Indirect Protective Effect of Influenza
 Vaccination in the United States". In: American Journal of Epidemiology 186.1 (2017), pp. 92–
 100. ISSN: 14766256. DOI: 10.1093/aje/kwx037.
- [4] Nimalan Arinaminpathy et al. "Impact of Cross-Protective Vaccines on Epidemiological and Evolutionary Dynamics of Influenza". In: *Proceedings of the National Academy of Sciences of the United States of America* 109.8 (2012), pp. 3173–3177. ISSN: 00278424. DOI: 10.1073/pnas.
 1113342109.
- ³¹⁴ [5] Nimalan. Arinaminpathy et al. "Population Implications of the Deployment of Novel Universal
 ³¹⁵ Vaccines against Epidemic and Pandemic Influenza". In: *Journal of The Royal Society Interface*³¹⁶ 17.164 (Mar. 2020), p. 20190879. DOI: 10.1098/rsif.2019.0879.
- [6] Jacob Bock Axelsen et al. "Multiannual Forecasting of Seasonal Influenza Dynamics Reveals
 Climatic and Evolutionary Drivers". In: *Proceedings of the National Academy of Sciences* 111.26
 (July 2014), pp. 9538–9542. DOI: 10.1073/pnas.1321656111. URL: https://www.pnas.org/
 doi/10.1073/pnas.1321656111 (visited on 03/09/2023).
- [7] Benjamin D. Dalziel et al. "Urbanization and Humidity Shape the Intensity of Influenza Epi demics in U.S. Cities". In: Science 362.6410 (Oct. 5, 2018), pp. 75–79. DOI: 10.1126/science.
 aat6030. URL: https://www.science.org/doi/10.1126/science.aat6030 (visited on
 08/29/2022).
- [8] Xiangjun Du et al. "Evolution-Informed Forecasting of Seasonal Influenza A (H3N2)". In:
 Science translational medicine 9.413 (Oct. 2017), eaan5325. ISSN: 1946-6234. DOI: 10.1126/
 scitranslmed.aan5325.
- Jonathan Dushoff et al. "Dynamical Resonance Can Account for Seasonality of Influenza Epidemics". In: *Proceedings of the National Academy of Sciences* 101.48 (Nov. 30, 2004), pp. 16915– 16916. DOI: 10.1073/pnas.0407293101. URL: https://www.pnas.org/doi/full/10.1073/ pnas.0407293101 (visited on 08/14/2023).
- [10] Neil M. Ferguson, Alison P. Galvani, and Robin M. Bush. "Ecological and Immunological Determinants of Influenza Evolution". In: *Nature* 422.6930 (Mar. 2003), pp. 428–433. ISSN: 1476-4687.
 DOI: 10.1038/nature01509.

- ³³⁵ [11] *FluView*. URL: https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html.
- Julia R. Gog and Bryan T. Grenfell. "Dynamics and Selection of Many-Strain Pathogens". In:
 Proceedings of the National Academy of Sciences 99.26 (Dec. 2002), pp. 17209–17214. ISSN:
 0027-8424, 1091-6490. DOI: 10.1073/pnas.252512799.
- Katelyn M. Gostic et al. "Potent Protection against H5N1 and H7N9 Influenza via Childhood
 Hemagglutinin Imprinting". In: Science 354.6313 (Nov. 2016), pp. 722-726. ISSN: 0036-8075,
 1095-9203. DOI: 10.1126/science.aag1322.
- ³⁴² [14] Florian Krammer. "The Human Antibody Response to Influenza A Virus Infection and Vacci³⁴³ nation". In: *Nature Reviews Immunology* 19.6 (June 2019), pp. 383–397. ISSN: 1474-1741. DOI:
 ³⁴⁴ 10.1038/s41577-019-0143-6.
- ³⁴⁵ [15] Florian Krammer and Peter Palese. "Advances in the Development of Influenza Virus Vaccines".
 ³⁴⁶ In: *Nature Reviews Drug Discovery* 14.3 (Mar. 2015), pp. 167–182. ISSN: 1474-1784. DOI: 10.
 ³⁴⁷ 1038/nrd4529.
- Patrick J. Lillie et al. "Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza
 Vaccine, MVA-NP+M1, in Humans". In: *Clinical Infectious Diseases* 55.1 (July 2012), pp. 19–
 25. ISSN: 1058-4838. DOI: 10.1093/cid/cis327.
- [17] Raffael Nachbagauer et al. "A Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccine
 Approach Induces Broad and Long-Lasting Immunity in a Randomized, Placebo-Controlled
 Phase I Trial". In: *Nature Medicine* 27.1 (Jan. 2021), pp. 106–114. ISSN: 1546-170X. DOI: 10.
 1038/s41591-020-1118-7.
- Todd L. Parsons et al. "The Probability of Epidemic Burnout in the Stochastic SIR Model with
 Demography". Aug. 2023. URL: https://hal.science/hal-04190409 (visited on 12/07/2023).
- Olivier Restif and Bryan T Grenfell. "Integrating life history and cross-immunity into the
 evolutionary dynamics of pathogens". In: *Proceedings of the Royal Society B: Biological Sciences* 273.1585 (Feb. 2006), pp. 409-416. ISSN: 0962-8452. DOI: 10.1098/rspb.2005.3335. URL:
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560197/ (visited on 06/09/2021).
- [20] Olivier Restif and Bryan T Grenfell. "Vaccination and the dynamics of immune evasion". In:
 Journal of the Royal Society Interface 4.12 (Feb. 2007), pp. 143-153. ISSN: 1742-5689. DOI: 10.
 1098/rsif.2006.0167. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358969/
 (visited on 06/09/2021).
- Rahul Subramanian et al. "Universal or Specific? A Modeling-Based Comparison of Broad Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines". In: *PLoS Com- putational Biology* 12.12 (2016), pp. 1–17. ISSN: 15537358. DOI: 10.1371/journal.pcbi.
 1005204.
- ³⁶⁹ [22] Christine B. Turley et al. "Safety and Immunogenicity of a Recombinant M2e–Flagellin In³⁷⁰ fluenza Vaccine (STF2.4xM2e) in Healthy Adults". In: *Vaccine* 29.32 (July 2011), pp. 5145–
 ³⁷¹ 5152. ISSN: 0264-410X. DOI: 10.1016/j.vaccine.2011.05.041.

- ³⁷² [23] U.S. Influenza Surveillance: Purpose and Methods CDC. Oct. 2022. URL: https://www.
 ³⁷³ cdc.gov/flu/weekly/overview.htm%5C#Outpatient.
- ³⁷⁴ [24] Cécile Viboud et al. "Beyond Clinical Trials: Evolutionary and Epidemiological Considerations
 ³⁷⁵ for Development of a Universal Influenza Vaccine". In: *PLOS Pathogens* 16.9 (Sept. 2020). Ed.
 ³⁷⁶ by Tom C. Hobman, e1008583. ISSN: 1553-7374. DOI: 10.1371/journal.ppat.1008583.
- Wan Yang, Eric H. Y. Lau, and Benjamin J. Cowling. "Dynamic Interactions of Influenza
 Viruses in Hong Kong during 1998-2018". In: *PLOS Computational Biology* 16.6 (June 2020),
 e1007989. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.1007989.
- ³⁸⁰ [26] Wan Yang, Eric H. Y. Lau, and Benjamin J. Cowling. "Dynamic interactions of influenza
 ³⁸¹ viruses in Hong Kong during 1998-2018". en. In: *PLOS Computational Biology* 16.6 (June 2020).
- Publisher: Public Library of Science, e1007989. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.
- 1007989. URL: https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.
- ³⁸⁴ pcbi.1007989 (visited on 06/08/2021).
- ³⁸⁵ [27] Wan Yang et al. "Forecasting Influenza Epidemics in Hong Kong". In: *PLOS Computational* ³⁸⁶ Biology 11.7 (July 2015), e1004383. ISSN: 1553-7358. DOI: 10.1371/journal.pcbi.1004383.

³⁸⁷ S1 Supplementary information

- ³⁸⁸ The supplementary information includes:
- Dataset and code availability
- Ordinary differential equations of the model, Supplementary Tables S1-2
- Invasion analysis of a pandemic variant
- Supplementary Figures S1-11

³⁹³ S1.1 Dataset and codes

 $_{394}$ See R codes and data on our GitHub repository: https://github.com/kikiyang/broadFluVacModel

³⁹⁵ S1.2 Ordinary differential equations of the model

 $_{\tt 396}$ See Table S1 and S2 below for a description of all symbols in the model.

$$\begin{split} dS/dt &= \mu - (\rho + \mu)S - \beta_1 S(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - \beta_2 S(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) + \sigma_1 R_1 + \sigma_2 R_2 + \sigma_V V \\ dI_1/dt &= \beta_1 S(I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\gamma_1 + \mu)I_1 \\ dR_1^T/dt &= \gamma_1 I_1 + \sigma_{V_2} R_1^{V,T} - (\sigma_T + \mu + \rho_2) R_1^T \\ dR_1/dt &= \sigma_2 R_{1,2} + \sigma_T R_1^T + \sigma_{V_2} R_1^V - \beta_2 (1 - \theta_1) R_1 (I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\mu + \sigma_1 + \rho_2) R_1 \\ dI_{1,2}/dt &= \beta_2 (I - \theta_1) R_1 (I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\mu + \gamma_2) I_{1,2} \\ dI_2/dt &= \beta_2 S(I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\gamma_2 + \mu) I_2 \\ dR_2^T/dt &= \gamma_2 I_2 + \sigma_V R_2^{V,T} - (\mu + \sigma_T + \rho_1) R_1^T \\ dR_2/dt &= \sigma_1 R_{1,2} + \sigma_T R_2^T + \sigma_{V_1} R_2^V - \beta_1 (1 - \theta_2) R_2 (I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\mu + \sigma_2 + \rho_1) R_2 \\ dI_{2,1}/dt &= \beta_1 (1 - \theta_2) R_2 (I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\mu + \gamma_1) I_{2,1} \\ dV/dt &= \rho S + \sigma_1 R_1^V + \sigma_2 R_2^V - (\mu + \sigma_V) V - \beta_2 (1 - \tau_1) V (I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - \beta_1 (1 - \tau_2) V (I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\gamma_1 + \mu) I_1^V \\ dI_1^V/dt &= \beta_1 (1 - \tau_2) V (I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\gamma_1 + \mu) I_1^V \\ dR_1^{V,T}/dt &= \gamma_1 I_1^V + \rho_2 R_1^T - (\sigma_{V_2} + \sigma_T + \mu) R_1^{V,T} \\ dR_1^V/dt &= \beta_2 (1 - \theta_1) (1 - \tau_1) R_1^V (I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\sigma_1 + \sigma_{V_2} + \mu) R_1^V \\ dI_{2,2}^V/dt &= \beta_2 (1 - \theta_1) (1 - \tau_1) R_1^V (I_2 + I_{1,2} + I_2^V + I_{1,2}^V) - (\sigma_1 + \sigma_{V_2} + \mu) R_1^V \\ dI_{2,2}^V/dt &= \gamma_2 I_2^V + \rho_1 R_2^T - (\sigma_{V_1} + \sigma_T + \mu) R_2^{V,T} \\ dR_2^V/dt &= \gamma_1 R_{1,2}^V + \sigma_T R_2^{V,T} + \rho_1 R_2 - \beta_1 (1 - \theta_2) (1 - \tau_2) R_2^V (I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\sigma_2 + \sigma_{V_1} + \mu) R_2^V \\ dI_{2,1}^V &= \beta_1 (1 - \theta_2) (1 - \tau_2) R_2^V (I_1 + I_{2,1} + I_1^V + I_{2,1}^V) - (\sigma_1 + \sigma_{V_1} + \mu) R_2^V \\ dR_2^V/dt &= \gamma_1 I_{2,1}^V + \gamma_2 I_{1,2}^V - (\sigma_1 + \sigma_2 + \mu) R_{1,2}^V \\ dR_2^V/dt &= \gamma_1 I_{2,1}^V + \gamma_2 I_{1,2}^V - (\sigma_1 + \sigma_2 + \mu) R_{1,2}^V \\ dR_{1,2}^V/dt &= \gamma_1 I_{2,1}^V + \gamma_2 I_{1,2}^V - (\sigma_1 + \sigma_2 + \mu) R_{1,2}^V \\ dR_{1,2}^V/dt &= \gamma_1 I_{2,1}^V + \gamma_2 I_{1,2}^V - (\sigma_1 + \sigma_2 + \mu) R_{1,2}^V$$

	Table 51. Compartments in the model
Compartment	Definition
\overline{S}	Susceptibles to both groups
V	Vaccinated
I_i	Primary infections by group i
T	Secondary infections by group j with a primary in-
$I_{i,j}$	fection by group i
τV	Infected individuals by strain j , who has been vacci-
$I_{i,j}$	nated (and had group i infection before)
	Strain-transcending immune to both strains by pri-
$R_{i,j}^T$	mary infection by group i (and a secondary infection
	by group j)
DV	Vaccinated and also immune to group i (and group
$\kappa_{i,j}$	j from infection)
$D^{V,T}$	Vaccinated and also strain-transcending immune to
\mathbf{n}_i	group i by previous infection by group i
R_i	Immune to group i
$R_{i,j}$	Immune to both group i and group j

Table S1: Compartments in the model

Table S2:	Parameters	$_{\mathrm{in}}$	$_{\rm the}$	model
-----------	------------	------------------	--------------	-------

Parameter	Definition	Value	Source of the valu
$R_0^{(i)}$	Basic reproductive num- ber	1.44 (H1), 1.60 (H3)	[25]
β_i	Transmission rate of clade i	$\beta_i(t) = R_0^{(i)}(\gamma_i + \mu)(1 + a\cos(2\pi t)), \ \beta_0 = R_0(\gamma + \mu)$	/
a	amplitude of sinusoidal seasonal forcing function	0.04	See methods 2.2
γ_i	Recovery rate from infec- tion of clade i	365/2.64 (H1), 365/3.03 (H3)	[25]
σ_T	Waning rate of strain- transcending immunity in- duced by infection	365/60	[10]
σ_i	Waning rate of immunity induced by natural infec- tion of clade i	1/3.12 (H1), 1/2.28 (H3)	[25]
$ heta_i$	ity of the other clade con- ferred by infection of clade i	/	See methods 2.2
σ_V	Waning rate of vaccinal immunity	$\sigma_V = k_2 \sigma$	/
σ_{V_i}	Waning rate of immunity of the vaccine targeting clade i	$\sigma_{V_i} = k_2 \sigma_i$	/
ρ	Vaccination rate	0-1	/
$ ho_i$	Vaccination rate of the vaccine targeting clade i	ρ	/
$ au_i$	Reduction in susceptibil- ity of the other group conferred by vaccination against clade i	$ au = k_1 heta$	/

³⁹⁷ S1.3 Invasion analysis of a pandemic variant

We used a similar method as in the previous study [20]. However, our model relaxes the assumption that two strains have the same reproductive ratio and other important epidemiological parameters. We first prepare a population where H3 clade is endemic in the presence of H3 vaccine and H1 clade is absent. We simulate the system for 600 years at semi-weekly time steps to bring H3 to endemic equilibrium, given by

$$\begin{cases}
\hat{S} = \frac{\gamma_2 + \mu}{\beta_2} = \frac{1}{R_0^2} \\
\hat{I}_2 = \frac{\mu + \sigma_T}{\gamma_2} \hat{R}_2^T \\
\hat{R}_2^T = \frac{\mu + \sigma_2}{\sigma_T} \hat{R}_2 \\
\hat{V} = \frac{\rho}{\mu + \sigma_V} \hat{S}
\end{cases}$$
(S2)

where R_0^2 is the basic reproductive ratio of H3. The critical vaccination rate p_c makes the system at disease-free equilibrium, which gives the two following conditions:

$$\begin{cases} R_0^2 > 1 \\ p < p_c \equiv (R_0^2 - 1)(\sigma_V + \mu) \end{cases}$$
(S3)

Hence, H3 clade is eliminated when $\sigma_V < \frac{1}{R_0^2 - 1} - \mu$ and $p < (R_0^2 - 1)(\sigma_V + \mu)$.

Next, we introduce a pandemic variant into the population at a very low frequency $(I_1 = 10^{-6})$. The initial invasion dynamics of the pandemic variant approximately follow the equations below.

$$\frac{dI_1}{dt} = \beta_1 \hat{S} (I_1 + I_{2,1} + I_1^V) - (\gamma_1 + \mu) I_1
\frac{dI_{2,1}}{dt} = \beta_1 (1 - \theta_2) \hat{R}_2 (I_1 + I_{2,1} + I_1^V) - (\mu + \gamma_1) I_{2,1}
\frac{dI_1^V}{dt} = \beta_1 (1 - \tau_2) \hat{V} (I_1 + I_{2,1} + I_1^V) - (\gamma_1 + \mu) I_1^V$$
(S4)

Let $X_2(t) = I_1(t) + I_{2,1}(t) + I_1^V(t)$, and assume that initially $X_2(t)$ approximately grows or decreases exponentially during a short time interval. This exponential behaviour can be written as Ce^{xt} , where C is a positive constant and x is the invasion rate of the pandemic variant. The equations S4 can be solved as:

$$\begin{cases} I_{1}(t) = \frac{\beta_{1}}{\gamma_{1}+\mu+x} \hat{S}Ce^{xt} + K_{1}e^{-(\gamma_{1}+\mu)t} \\ I_{2,1}(t) = K_{2,1}e^{-(\gamma_{1}+\mu)t} + \frac{1-\theta_{2}}{\gamma_{1}+\mu+x}C\beta_{1}\hat{R}_{2}e^{xt} \\ I_{1}^{V}(t) = K_{1}^{V}e^{-(\gamma_{1}+\mu)t} + \frac{1-\tau_{2}}{\gamma_{1}+\mu+x}C\beta_{1}\hat{V}e^{xt} \end{cases}$$
(S5)

where K_1 , $K_{2,1}$, K_1^V are three constants that depend on initial conditions. If $x > -(\gamma_1 + \mu)$, then the first term in each function rapidly becomes negligible. Since we initially assumed that $I_1(t) + I_{2,1}(t) + I_1^V(t) = Ce^{xt}$, then x must satisfy the following relation:

$$f(x) \equiv \frac{\beta_1}{x + \gamma_1 + \mu} (\hat{S} + (1 - \theta_2)\hat{R}_2 + (1 - \tau_2)\hat{V}) = 1.$$
(S6)

⁴¹⁵ f(x) is a continuous, decreasing function over $(-(\gamma_1 + \mu), \infty)$. If cross-immunity is perfect, i.e. ⁴¹⁶ $\theta_2 = \tau_2 = 1$, then $f(x) = \frac{\beta_1(\gamma_2 + \mu)}{\beta_2(x + \gamma_1 + \mu)} = 1$, therefore $x = \beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1})$ is a solution for (S6). ⁴¹⁷ Otherwise, $f(\beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1})) > 1$, so f(x) admits a unique solution $x > \beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1})$. When $R_0^2 < R_0^1$, ⁴¹⁸ i.e., the basic reproductive ratio of the endemic strain is smaller than the invading variant, x > 0, ⁴¹⁹ i.e., the pandemic always emerges. Otherwise, $\beta_1(\frac{1}{R_0^2} - \frac{1}{R_0^1}) < 0$, and therefore x could be negative 420 or positive. In our case, where $\theta_2 = 0$, the unique solution can be written as below.

$$x = \beta_1 (\hat{S} + \hat{R}_2 + (1 - \tau_2)\hat{V}) - (\gamma_1 + \mu)$$
(S7)

We can see that the vaccine characteristics (σ_V , τ_2 and ρ) and their relationship with the pathogen epidemiological parameters decide if pandemic emergence could be successful.

423 S1.4 Figures



Figure S1: Sensitivity test for initial conditions. The initial condition 1 assumes susceptible population is 89.9%, H1 infection is 0.01% and H3 infection is 0.1%. The initial condition 2 assumes the susceptibles are 89.9%, H1 infection is 0.1% and H3 infection is 0.01%. Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity strengths (columns, defined as $k_1 = \frac{\tau_i}{\theta_i}$), with changes of vaccination rate (%) per week (x axis). The results are calibrated with the best-fitting parameters ($\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$). Other parameters are the same as in 2.



Figure S2: Sensitivity test for initial conditions. Parameters are the same as in S1. Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *durations* (columns, defined as $k_2 = \frac{\sigma_i}{\sigma_V}$), with changes of vaccination rate (%) per week (x axis).



Figure S3: Weekly incidence of human influenza H1N1 (in red) and H3N2 (in blue) in the United States. The grey area is pandemic seasons from 2009-07-01 to 2011-07-01; they are excluded in the model calibration.



Figure S4: The optimization metric distribution across the parameter space of a, θ_1 and θ_2 . Each grid represents a combination of the parameters, the colour of which shows the sum of the absolute distance between simulation and data [11] of three summary statistics, including I) correlation between H1 and H3 seasonal incidence, II) coefficient of variation of H1 (and H3) seasonal incidence, III) auto-correlation of H1 (and H3) seasonal incidence.



Figure S5: The distribution of the optimization metric (< 3) across the parameter space of a, θ_1 and θ_2 . Each grid represents a combination of the parameters, the colour of which shows the sum of the absolute distance between simulation and data [11] of three summary statistics, including I) correlation between H1 and H3 seasonal incidence, II) coefficient of variation of H1 (and H3) seasonal incidence, III) auto-correlation of H1 (and H3) seasonal incidence.



Figure S6: Occurrence counts of the same parameter sets of θ_1 and θ_2 with different *a* that gives optimization metric value smaller than 3.



Figure S7: Histogram of correlation between H1 and H3 seasonal incidence (left-top panel), auto-correlation of H1 (and H3) incidence (right-top panel) and coefficient of variation of H1 (and H3) incidence (left-bottom panel) of every 12-yer period of the 2000-year simulation with first 800 years as burn-in, using $\theta_1 = 0.8, \theta_2 = 0.5, a = 0.04$ as the parameters. Dashed lines show the metric values in the incidence data. Blue and red colours represent H3 and H1 respectively.



Figure S8: Histogram of correlation between H1 and H3 seasonal incidence (left-top panel), auto-correlation of H1 (and H3) incidence (right-top panel) and coefficient of variation of H1 (and H3) incidence (left-bottom panel) of every 12-yer period of the 2000-year simulation with first 800 years as burn-in, using $\theta_1 = 0.55$, $\theta_2 = 0.35$, a = 0.04 as the parameters. Dashed lines show the metric values in the incidence data. Blue and red colours represent H3 and H1 respectively.



Figure S9: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *strengths* (columns, defined as $k_1 = \frac{\tau_i}{\theta_i}$), with changes of vaccination rate (%) per week (x axis). The results are calibrated with the moderate-fitting parameters ($\theta_1 = 0.55, \theta_2 = 0.35, a = 0.04$). Other parameters are the same as in 2.



Figure S10: Average weekly incidence of H1 and H3 subtypes per 1000 population (y axis) vaccinated by vaccines with different target clades (rows) and immunity *durations* (columns, defined as $k_2 = \frac{\sigma_i}{\sigma_V}$), with changes of vaccination rate (%) per week (x axis). The parameters are the same as in S9.



Figure S11: Persistence of the endemic variant 5 years after its emergence, measured by trough depth of its incidence ((the minimal incidence), under vaccination of different immunity strength (y axis), duration (row) and vaccination rate ρ (%) per week (x axis), with different basic reproduction number R_0^1 (column). The grey area is when the endemic strain fails to persist. The black curve indicate the transition between persistence and failure in the persistence of the endemic strain. Other parameters are same as those in Figure 4.



Figure S12: Deterministic trajectories after the pandemic strain (at the incidence of 10^{-6}) invades the endemic equilibrium of H3. Line types represent weak (20%), middle (40%), and strong (80%) susceptibility reduction against the pandemic strain (τ_2) by the vaccine. $R_0^2 = 3.2, 1/\sigma_V = 16(yr), \rho = 1.73\%$ per week. Other parameters are as in Figure 4.